期刊文献+

反相高效液相色谱法测定人血浆中兰索拉唑的浓度 被引量:15

Determination the Content of Lansoprazole in Human Plasma by RP-HPLC
下载PDF
导出
摘要 目的:建立反相高效液相色谱法测定人血浆中兰索拉唑的浓度。方法:色谱柱为Agilent Eclipse XDB C_(18)(150 mm×4.6 mm,5μm),流动相为0.01 mol·L^(-1)磷酸二氢铵(内含1‰正辛胺)-乙腈(66:34),流速为1.0 ml·min^(-1),检测波长为285 nm,内标为奥美拉唑。结果:兰索拉唑的线性范围为0.01-2.00μg·ml^(-1),回归方程为Y=0.0019C+0.0022(r=0.999 4);批内RSD为2.95%~3.25%,批间RSD为1.09%-1.95%。结论:本方法操作简便,测定结果准确,检测限较低,重现性好,可用于兰索拉唑人体药物动力学研究。 Objective: To establish a RP-HPLC method for the determination the content of Lansoprazole in human plasma. Method: The Agilent Eclipse XDB C18 column (150 mm × 4.6 mm, 5 μm) was used with mobile phase of 0.01 mol·L^-1 ammonium hihydrogen phosphate-acetonitrile (66: 34) to which 1%o Octylamine was added. The flow rate was 1.0 ml·min^-1. The detection wavelength was 285 nm(lansoprazole) and 305nm ( omeprazole). Internal standard was omeprazole. Result: The linear range of the calibration was (0.01-2.00)μg·ml^-1( Y=0.0019C +0.002 2, r =0.999 4). Within-day RSD was 2.95%-3.25%. Between-day RSD was 1.09%-1.95%. Conclusion: The method is simple, accurate, it can be used in the phamarmacokinetic study of lansoprazole.
出处 《中国药师》 CAS 2006年第9期823-825,共3页 China Pharmacist
关键词 兰索拉唑 反相高效液相色谱法 血浆浓度 Lansoprazole RP - HPLC Plasma concentration
  • 相关文献

参考文献6

二级参考文献31

  • 1张明,董永绥,万峰,李革.婴儿巨细胞病毒性肝炎外周血白细胞巨细胞病毒感染[J].中华儿科杂志,1995,33(1):10-12. 被引量:15
  • 2巨细胞病毒感染诊断试行标准[J].中华儿科杂志,1995,33(1):8-9. 被引量:87
  • 3Shizaki, Horai Y. Cytochrome P450 and the metabolism of proton pump inhibitors: emphasis on rabeprazole[J]. Aliment Pharmacol Ther, 1999, 13suppl 3: 27-36
  • 4Yang FQ. Chen GM, Nu Ly, et al. Effect of thymus protein oral solution in treating experimental gastric ulcer [J ]. Med Chin PLA (in Chinese), 1997,22(6):447-449
  • 5李云兰.奥美拉唑联合阿莫西林治疗消化性溃疡50例观察[J].中国医院药学杂志,2000,20(10):618-618.
  • 6de Morais SMF, Goldstein JA, Xie HG, Huang SL, Lu YQ,Xia H, et al. Identification Genetic analysis of the Smephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995; 58: 404-11.
  • 7Goldstein JA, Blaisdell J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. In: Johnson EF, Waterman MR, editors. Methods in Enzymology 272, Cytochrome P450. New York: Academic Press; 1996. p 210-8.
  • 8Karol MD, Granneman GR, Alexander k. Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography. J Chromatogr B 1995; 668:182-6.
  • 9Sohn DR, Kwon JT, Kim HK, Ishizaki T. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4hydroxylation phenotype status. Clin Pharmacol Ther 1997;61: 574-82.
  • 10Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C 19. Clin Pharmacol Ther 2001; 70: 484-92.

共引文献46

同被引文献56

引证文献15

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部